


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/551983/publications.pdf Version: 2024-02-01



SONC XU

#	Article	IF	CITATIONS
1	Effect of Upper Arm Position Changes on the Occurrence of Ipsilateral Shoulder Pain After Single-Operator Port Thoracoscopy. Frontiers in Surgery, 2022, 9, 823259.	0.6	1
2	Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement. Frontiers in Oncology, 2022, 12, 848779.	1.3	9
3	Establishment and characterization of a novel highly malignant lung cancer cell line <scp>ZX2021H</scp> derived from a metastatic lymph node lesion. Thoracic Cancer, 2022, , .	0.8	2
4	Lobe-Specific Analysis of Sublobar Lung Resection for NSCLC Patients with Tumors ≤2 cm. Cancers, 2022, 14, 3265.	1.7	3
5	Prognostic Significance of Lymph Node Count Removed at Sublobar Resection in Pathologic Stage IA Non–Small-cell Lung Cancer: A Population-Based Analysis. Clinical Lung Cancer, 2021, 22, e563-e573.	1.1	7
6	The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. Frontiers in Oncology, 2021, 11, 567978.	1.3	6
7	Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. Cancers, 2021, 13, 1397.	1.7	9
8	A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation. Cancer Research and Treatment, 2021, 53, 601-606.	1.3	3
9	Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China. Patient Preference and Adherence, 2021, Volume 15, 775-783.	0.8	3
10	Primary ciliated muconodular papillary tumor: A rare pulmonary disease and literature review of 65 cases. Thoracic Cancer, 2021, 12, 1917-1922.	0.8	9
11	Prognostic value of ferroptosisâ€ŧelated genes in patients with lung adenocarcinoma. Thoracic Cancer, 2021, 12, 1890-1899.	0.8	13
12	Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching's Study. Frontiers in Oncology, 2021, 11, 610638.	1.3	14
13	Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. Translational Lung Cancer Research, 2021, 10, 2298-2305.	1.3	0
14	First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 657545.	1.3	6
15	Frequent Genetic Alterations and Their Clinical Significance in Patients With Thymic Epithelial Tumors. Frontiers in Oncology, 2021, 11, 667148.	1.3	6
16	Use of crizotinib as neoadjuvant therapy for nonâ€small cell lung cancers patient with ROS1 rearrangement: A case report. Thoracic Cancer, 2021, 12, 2815-2818.	0.8	8
17	Current and potential biomarkers in gastric cancer: a critical review of the literature. Future Oncology, 2021, 17, 3383-3396.	1.1	16
18	LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 711928.	1.6	2

Song Xu

#	Article	IF	CITATIONS
19	The Epidemiology of Ground Glass Opacity Lung Adenocarcinoma: A Network-Based Cumulative Meta-Analysis. Frontiers in Oncology, 2020, 10, 1059.	1.3	8
20	The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2184-2187.	1.3	2
21	Circular RNA Signature in Lung Adenocarcinoma: A MiOncoCirc Database-Based Study and Literature Review. Frontiers in Oncology, 2020, 10, 523342.	1.3	10
22	Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data. Cancer Medicine, 2020, 9, 7686-7694.	1.3	9
23	Outcomes of lobectomy on pulmonary function for early stage nonâ€small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD). Thoracic Cancer, 2020, 11, 1784-1789.	0.8	14
24	Anterior mediastinal metastasis of primary fallopian tube adenocarcinoma: a case report. Journal of Cardiothoracic Surgery, 2020, 15, 77.	0.4	1
25	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncolmmunology, 2020, 9, 1781333.	2.1	34
26	Preliminary recommendations for lung surgery during COVID â€19 epidemic period. Thoracic Cancer, 2020, 11, 1372-1374.	0.8	10
27	The impact of programmed death-ligand 1 expression on the prognosis of early-stage resected non-small cell lung cancer: A meta-analysis of literatures Journal of Clinical Oncology, 2020, 38, e21004-e21004.	0.8	0
28	Sublobar resection versus lobectomy for early-stage pulmonary carcinoid tumors with three centimeters or less in size: A population-based study Journal of Clinical Oncology, 2020, 38, e21062-e21062.	0.8	0
29	Clinical and molecular characteristics of TSC1/2 mutant lung cancer Journal of Clinical Oncology, 2020, 38, e21647-e21647.	0.8	0
30	Clinicopathological characteristics and genetic analysis of pulmonary carcinoid tumors: A single‑center retrospective cohort study and literature review. Oncology Letters, 2020, 19, 2446-2456.	0.8	5
31	Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential. Thoracic Cancer, 2019, 10, 1111-1128.	0.8	1
32	Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. Cancer Biology and Medicine, 2019, 16, 556-564.	1.4	36
33	Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?. Leukemia, 2018, 32, 1500-1514.	3.3	77
34	Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review. Thoracic Cancer, 2018, 9, 316-323.	0.8	16
35	Clinical implication of MEN1 mutation in surgically resected thymic carcinoid patients. Journal of Thoracic Disease, 2018, 10, E125-E129.	0.6	9
36	Serum microRNA-139-5p is downregulated in lung cancer patients with lytic bone metastasis. Oncology Reports, 2018, 39, 2376-2384.	1.2	24

Song Xu

#	Article	IF	CITATIONS
37	The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing. OncoTargets and Therapy, 2018, Volume 11, 919-932.	1.0	5
38	Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma. Thoracic Cancer, 2018, 9, 974-988.	0.8	9
39	Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance. Thoracic Cancer, 2017, 8, 693-697.	0.8	8
40	Primary pulmonary malignant fibrous histiocytoma: case report and literature review. Journal of Thoracic Disease, 2017, 9, E702-E708.	0.6	9
41	Examined lymph node count in non-small-cell lung cancer: will it be a decision making approach in treatment of NSCLC?. Journal of Thoracic Disease, 2017, 9, E480-E482.	0.6	0
42	Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. Oncotarget, 2017, 8, 100754-100763.	0.8	5
43	Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Letters, 2016, 377, 17-24.	3.2	106
44	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Letters, 2016, 370, 324-331.	3.2	93
45	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget, 2016, 7, 84951-84964.	0.8	41
46	Sarcoidosis misdiagnosed as malignant tumors: a case report. World Journal of Surgical Oncology, 2015, 13, 333.	0.8	9
47	Thyroid transcription factor-1 expression is significantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in Chinese patients with lung adenocarcinoma. OncoTargets and Therapy, 2015, 8, 2469.	1.0	9
48	Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Letters, 2014, 353, 145-152.	3.2	44
49	Vorinostat-induced bone loss might be related to drug toxicity. Bone, 2013, 57, 384-385.	1.4	4
50	Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacologica Sinica, 2013, 34, 699-709.	2.8	53
51	Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. PLoS ONE, 2013, 8, e79752.	1.1	64
52	In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo. Biochemical and Biophysical Research Communications, 2012, 424, 391-397.	1.0	12
53	Upregulation of SEPT7 Gene Inhibits Invasion of Human Glioma Cells. Cancer Investigation, 2010, 28, 248-258.	0.6	11